Search

Your search keyword '"Nogova L"' showing total 271 results

Search Constraints

Start Over You searched for: Author "Nogova L" Remove constraint Author: "Nogova L"
271 results on '"Nogova L"'

Search Results

1. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

2. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

3. 9P Small-scale ROS1 aberrations: Functional impact and therapeutic potential

4. EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients

5. EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations

6. 991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)

7. 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort

8. 1729P The biological effect of small-scale ROS1 aberrations: An in silico analysis

9. P13.03.A Radiomics for the non-invasive assessment of the PDL-1 expression in patients with non-small cell lung cancer brain metastases

10. KS02.7.A Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors

12. The fading relevance of the quantity of brain metastases in patients with non-small cell lung cancer

15. Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors

16. EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)

17. ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics

18. The biological effect of small-scale ROS1 aberrations: An in silico analysis

19. Small-scale ROS1 aberrations: Functional impact and therapeutic potential

20. BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort

21. 52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics

24. 1431P The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance

30. MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab: ID 439

34. FP14.04 Resistance to MET Inhibition in MET Driven NSCLC and Response after Switching from Type I to Type II MET Inhibitors

36. EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data

37. Small Cell Lung Cancer - Filling the gap between science and patients

38. KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup

39. FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC

47. EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer - preliminary data on safety and tolerability

Catalog

Books, media, physical & digital resources